Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
5.5
Expiration
Nov 20, 2026
DTE
7d
Moneyness
ITM
Intrinsic
$0.51
IBRX 5.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $2.58 | -21.10% | 1 | 9 |
| Nov 20, 2026 | 7d | — | — | 0 | 23 |
| Nov 27, 2026 | 14d | — | — | 0 | 0 |
| Dec 4, 2026 | 21d | $2.95 | +0.00% | 2 | 4 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $2.95 | -4.84% | 9 | 7,765 |
| Jan 21, 2028 | 434d | $4.18 | -3.69% | 1 | 3,712 |
IBRX Nearby Strikes · Nov 20, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 2 C | $6.35 | -0.78% | 10 | 36 | ITM |
| 3 C | $5.20 | -9.25% | 21 | 20 | ITM |
| 3.5 C | — | — | 0 | 0 | ITM |
| 4 C | $4.45 | +6.71% | 1 | 19 | ITM |
| 4.5 C | $4.19 | +0.00% | 6 | 6 | ITM |
| 5 C | $4.85 | -6.73% | 4 | 8 | ITM |
| 5.5 C | — | — | 0 | 23 | ITM |
| 6 C | $2.44 | -30.29% | 2 | 330 | ITM |
| 6.5 C | $2.08 | +0.00% | 2 | 151 | OTM |
| 7 C | $1.50 | -21.05% | 6 | 2,283 | OTM |
| 7.5 C | $1.27 | +0.00% | 45 | 329 | OTM |
| 8 C | $0.85 | -34.62% | 178 | 2,043 | OTM |
| 8.5 C | $0.70 | -11.39% | 21 | 160 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.